Ari M. Melnick
Director
Research Interests
Make your next move.
Prepare your application
Review drafts before you send them.
Explore related searches
Articles (29)
Combination therapies offer promise for improving cancer treatment efficacy and preventing recurrence. Preclinical screening strategies can prioritize synergistic drug combinations. However, identifying optimal combinations tailored to specific cancer subtypes and patients is challenging due to the vast number of possibilities and tumor heterogeneity. To address this gap, we developed PAIRWISE which explicitly modeled synergistic effects of drug combinations in cancer cell lines or tumor samples. PAIRWISE outperformed competing models with an AUROC of 0.847 on held-out cancer cell lines. When applied to an independent dataset with Bruton Tyrosine Kinase inhibitors in Diffuse Large B Cell Lymphoma, PAIRWISE accurately predicted synergistic combinations with an AUROC of 0.720. We validated 30 approved or investigational agents for DLBCL treatment and their synergy with BTKi in HTS. PAIRWISE showed strong concordance with in vitro screening results. These findings demonstrate the ability of PAIRWISE to nominate effective personalized drug combinations, accelerating precision oncology development.
Year:
2026
Supplementary Figure S1 shows correlation of EZH2 gene expression with FGA in METABRIC and TCGA breast cancer cohort suggests a link between EZH2 and CIN. Supplementary Figure S2 shows correlation between fraction genome altered (FGA) and EZH2 gene expression in TCGA LUAD cohort. Supplementary Figure S3 shows increased CIN in various TNBC, non-TNBC and and RPE1 cells and impact of EZH2 inhibition. Supplementary Figure S4 shows EZH2 inhibition and cell cycle analysis. Supplementary Figure S5 shows CUT & RUN seq and RNA-seq analysis. Supplementary Figure S6 shows visualization and experimental validation of EZH2 target genes. Supplementary Figure S7 shows EZH2 mediated TNKS regulates CIN. Supplementary Figure S8 shows multipolar mitosis and supernumerary centrosome analysis of the TNKS KO cells. Supplementary Figure S9 shows correlation of EZH2, CPAP and aneuploidy and effect of EZH2 inhibition on CPAP expression and cell cycle analysis of TNKSWT and TNKSKO LM2 cells. Supplementary Figure S10 shows impact of CIN modulation on proliferation and metastatic progression in EZH2 WT and EZH2 KO cells.
Year:
2026
Chromosomal instability (CIN) and epigenetic reprogramming are central drivers of breast cancer progression, yet the mechanisms connecting them remain elusive. Here, we uncover a direct role for EZH2 histone methyltransferase in promoting CIN in triple-negative breast cancer. Across breast cancers, EZH2 expression correlates with copy-number alterations, and its catalytic activity is associated with increased CIN in metastasis-initiating cells. Pharmacologic EZH2 inhibition suppresses CIN, revealing an unexpected vulnerability. Integrated chromatin and transcriptome profiling identified tankyrase (TNKS), a PARP, as a direct transcriptional target of EZH2. Mechanistically, EZH2-mediated TNKS suppression disrupts centrosomal P4.1–associated protein (CPAP), driving centrosome overduplication, multipolar mitosis, and exacerbated CIN. In vivo , CIN suppression is a critical mechanism underlying the antimetastatic effects of EZH2 inhibition. These findings delineate a previously unrecognized epigenetic mechanism governing CIN and establish EZH2 inhibitors as the first therapeutic agents capable of directly suppressing CIN, underscoring the need for trials with metastasis-focused endpoints. Significance: We elucidate epigenetic regulation of CIN through EZH2–TNKS–CPAP-axis and show that CIN suppression is important for the efficacy of EZH2 inhibition on metastasis. These mechanistic insights are informative for developing CIN-suppressing therapies.
Year:
2026
Impaired differentiation is a hallmark of myeloid malignancies 1,2 . Therapies that enable cells to circumvent the differentiation block, such as all- trans retinoic acid (ATRA) and arsenic trioxide (ATO), are by and large curative in acute promyelocytic leukaemia 3 , but whether ‘differentiation therapy’ is a generalizable therapeutic approach for acute myeloid leukaemia (AML) and beyond remains incompletely understood. Here we demonstrate that simultaneous inhibition of the histone demethylase LSD1 (LSD1i) and the WNT pathway antagonist GSK3 kinase 4 (GSK3i) robustly promotes therapeutic differentiation of established AML cell lines and primary human AML cells, as well as reducing tumour burden and significantly extending survival in a patient-derived xenograft mouse model. Mechanistically, this combination promotes differentiation by activating genes in the type I interferon pathway via inducing expression of transcription factors such as IRF7 (LSD1i) and the co-activator β-catenin (GSK3i), and their selective co-occupancy at targets such as STAT1, which is necessary for combination-induced differentiation. Combination treatment also suppresses the canonical, pro-oncogenic WNT pathway and cell cycle genes. Analysis of datasets from patients with AML suggests a correlation between the combination-induced transcription signature and better prognosis, highlighting clinical potential of this strategy. Collectively, this combination strategy rewires transcriptional programs to suppress stemness and to promote differentiation, which may have important therapeutic implications for AML and WNT-driven cancers beyond AML.
Year:
2025
Despite the approval of several new treatments for patients with B-cell lymphoma, there is still a large unmet need. Diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma (FL) are the 2 most common B-cell lymphoma subtypes, accounting for ∼50% of all cases. EZH2 heterozygous gain-of-function somatic driver mutations are frequently found in germinal center B-cell DLBCLs and FLs. An EZH2 inhibitor has shown durable responses in patients with relapsed or refractory FL, however a considerable fraction of the patients did not show an objective response. To identify alternative therapeutic strategies, we performed CRISPR/Cas9 knockout screens in B-cell lymphoma cells treated with or without an EZH2 inhibitor. This led to the identification of the histone methyltransferase DOT1L as a potential therapeutic target. Specifically, we showed that an EZH2 inhibitor synergizes with a DOT1L inhibitor in a panel of B-cell lymphoma cell lines regardless of the EZH2 mutation status. Mechanistically, we demonstrated that the 2 inhibitors cooperatively suppress DOT1L-regulated cell cycle genes, upregulate genes involved in interferon signaling, including antigen presenting genes, and ultimately drive B-cell differentiation by derepressing EZH2-regulated plasma cell signature genes. Furthermore, we demonstrated the effectiveness of this epigenetic combination strategy in a xenograft model, which led to significant abrogation of tumor growth. Together, our studies provide preclinical proof-of-concept for an epigenetic combination therapy to overcome resistance and improve durability of response for the treatment of B-cell lymphoma, warranting clinical investigation and illustrating an important convergent role of EZH2 and DOT1L in B-cell lymphomagenesis.
Year:
2025
Hematologic malignancies exhibit disparities in risk and outcomes across populations. A systematic review to identify prospective studies addressing disparities among patients with hematologic malignancies with an intervention or analysis at any level in the “Cells-to-Society” model identified few studies and demonstrated literature gaps, which experts have supplemented with relevant citations. This review presents current research on diagnosis, treatment, and survival disparities and explores the roles of biology, cancer centers, community outreach, patient advocacy, and policies. Emphasis is placed on multilevel collaborative approaches to promote equity in healthcare delivery and improve survival. Significance: This review underscores our shared responsibility to champion multidimensional strategies rooted in basic and translational science, community involvement, and societal responsiveness for a meaningful impact. Unifying themes include the need to enhance collaborative infrastructure to engage laboratory researchers, epidemiologists, data scientists, clinicians, patients, community leaders, and policymakers; patient-level support services; outreach, education, and navigation for patients at the community level; recruitment and retention of underrepresented groups in the healthcare and research workforce; and funding for these efforts.
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Diffuse large B cell lymphomas and follicular lymphomas show recurrent mutations in epigenetic regulators; among these are loss-of-function mutations in KMT2D and gain-of-function mutations in EZH2. To systematically explore the effects of these mutations on the wiring of the epigenetic network, we applied a single-cell approach to probe a wide array of histone modifications. We show that mutant-EZH2 elicits extensive effects on the epigenome of lymphomas, beyond alterations to H3K27 methylations, and is epistatic over KMT2D mutations. Utilizing the single-cell data, we present computational methods to measure epigenetic heterogeneity. We identify an unexpected characteristic of mutant-EZH2, but not KMT2D, in increasing heterogeneity, shedding light on a novel oncogenic mechanism mediated by this mutation. Finally, we present tools to reconstruct known interactions within the epigenetic network, as well as reveal potential novel cross talk between various modifications, supported by functional perturbations. Our work highlights novel roles for mutant-EZH2 in lymphomagenesis and establishes new concepts for measuring epigenetic heterogeneity and intra-chromatin connectivity in cancer cells.
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2022
Collaborators (42)
Elena I Rugarli
University of Cologne
Cem Meydan
Assistant Professor
Weill Cornell Medicine
Yuning Hong
La Trobe University
Ashley Laughney
Associate Professor
Weill Cornell Medicine
Olivier Elemento
Professor
Weill Cornell Medical College
David W. Scott
The University of British Columbia
Nemo Koi Ikonen
University of Helsinki
Gero Knittel
University Hospital Essen
Wendy Cozen
Professor
University of California, Irvine
Bethan Psaila
University of Oxford
Steven Treon
Professor
Harvard Medical School
Wendy Béguelin
Assistant Professor
NYU School of Medicine
Dylan McNally
Cornell University
Chijioke Nze
Assistant professor
The University of Texas MD Anderson Cancer Center
Melissa Hubisz
Cornell University
Liron Yoffe
Assistant Professor
Weill Cornell Medicine
Kristian Helin
CEO, Professor
Institute of Cancer Research
Leandro Cerchietti
Professor
NYU Langone Health
Jude Fitzgibbon
Professor in Personalised Cancer Medicine
Queen Mary University of London
Michelle Hildebrandt
Professor
The University of Texas MD Anderson Cancer Center
Darko Barisic
Assistant Professor
Weill Cornell Medicine
Shirong Liu
Senior Scientist
Dana-Farber Cancer Institute
Johana L Gutierrez
NewYork-Presbyterian Hospital/Weill Cornell Medical Center
Cihangir Duy
Assistant Professor
Fox Chase Cancer Center
Alan Melcher
Professor of Translational Immunotherapy
Institute of Cancer Research
Sylvain Nguyen
University of Oxford
Rulla Tamimi
Professor
Weill Cornell Medicine
Graziella Bosco
University of Cologne
Mehmet Samur
Senior Research Scientist
Dana-Farber Cancer Institute
Dinis Calado
Senior Group Leader
Babraham Institute
Reinhard Büttner
Head of Department
University of Cologne
Philipp Sergeev
University of Helsinki
Bjoern Chapuy
Professoor
Charité - Universitätsmedizin Berlin
Thuy Mai Van Nguyen
Imperial College London
qiang pan-hammarstrom
Professor, head of the Immunology Division
Karolinska University Hospital
Bastian von Tresckow
University of Cologne
Jerome Fortin
Assistant Professor
McGill University
Henry Withers
Research Assistant Professor of Oncology
Roswell Park Comprehensive Cancer Center
Jorge Castillo
Clinical Director, Bing Center for Waldenstrom Macroglobulinemia
Dana-Farber Cancer Institute
vivek mittal
Professor/Director
Weill Cornell Medicine
Hans Christian Reinhardt
-
Christopher Mason
Professor
Weill Cornell Medical College
Make your next move.
Prepare your application
Review drafts before you send them.